This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use


Blueberry Therapeutics commence Phase I/II clinical trial of lead product BB2603 25 April 2017

Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals.

> Read More

BPE strengthens new office with senior appointment 24 April 2017

BPE has strengthened its team in the North West with the appointment of Fiona Smith at its Daresbury base.

> Read More


Retrogenix receives its second prestigious Queen’s Award for Enterprise 21 April 2017

Retrogenix today announces that it has won a second Queen's Award for Enterprise in recognition of its outstanding growth in international trade. Serving a niche market in pharmaceutical development, Retrogenix's export sales now account for over 85% of the company's total turnover.

> Read More